Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Physiomics ( (GB:PYC) ) just unveiled an announcement.
Physiomics plc announced it will release its interim results on March 6, 2025, followed by a live investor presentation on March 10, 2025. This presentation, led by CEO Peter Sargent and Chairman Jim Millen, will be open to existing and potential shareholders, providing an opportunity to discuss the interim results and broader business aspects. This initiative reflects Physiomics’ commitment to transparency and engagement with its stakeholders, potentially enhancing its industry positioning and investor relations.
More about Physiomics
Physiomics plc is a company specializing in mathematical modelling, data science, and biostatistics to support the development of new therapeutics and personalized medicine solutions. The company leverages expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to help biotech and pharma companies optimize their drug development processes. Physiomics has contributed to over 100 commercial projects and has worked with clients such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and CRUK.
YTD Price Performance: -36.67%
Average Trading Volume: 4,859,459
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.44M
See more data about PYC stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue